Advanced Solid Tumors
Conditions
Keywords
Antibody-drug conjugates, Carcinoma, TGW101, TGW101-ADC, TRG001, TAG-72, Cancer
Brief summary
The primary objectives of this study are to evaluate the safety and tolerability of TGW101 and determine the recommended dosing regimen(s) for further study. The secondary objectives are to assess pharmacokinetics and preliminary antitumor activity.
Interventions
DRUGTGW101
TGW101 is a combination product comprising a chemically cleavable diabody drug conjugate (TGW101-ADC) and a corresponding small molecule chemical trigger (TRG001) administered separately.
Sponsors
Tagworks Pharmaceuticals BV
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Written informed consent prior to any study procedures. 2. Males or females 18 years or older. 3. Histologically or cytologically confirmed diagnosis of a solid tumor malignancy listed below, with radiographic evidence of disease progression based on Response Evaluation Criteria in Solid Tumors (RECIST v1.1), or for castration resistant prostate cancer (CRPC), Prostate Cancer Clinical Trials Working Group 3, after most recent treatment and locally advanced or metastatic disease at Screening: 1. Breast cancer (all subtypes). 2. Castrate-resistant prostate cancer. 3. Cervical cancer. 4. Endometrial cancer. 5. Esophageal, adenocarcinoma only. 6. Gastric/gastroesophageal junction (GEJ). 7. Non-squamous cell carcinoma of the head and neck, e.g., salivary gland neoplasms, with the exception of adenoid cystic carcinoma. 8. Non-small cell lung cancer, adenocarcinoma only. 9. Ovarian. 4. Refractory disease, intolerance to, or documented refusal of available standard therapy(ies) known to provide clinical benefit for the participant's solid tumor malignancy per Investigator judgment. 5. At least 1 measurable lesion per RECIST v1.1 except for participants with bone-only metastatic disease. 6. Biopsy pretreatment; if not possible, archival tissue block (preferred) or unstained formalin-fixed paraffin-embedded slides required. 7. Eastern Cooperative Oncology Group Performance Status 0-1. 8. Life expectancy of \> 3 months in the opinion of the Investigator. 9. Adequate hepatic, hematologic, and renal function.
Exclusion criteria
1. Active second malignancy or history of another malignancy within the last 2 years, with the exception of: treated non-melanoma skin cancers; treated carcinoma in situ (e.g., breast and cervix); controlled superficial carcinoma of the urinary bladder; T1a or b carcinoma of the prostate; papillary thyroid carcinoma Stage I treated surgically for cure. 2. Known symptomatic brain metastases. 3. Significant cardiovascular disease within 6 months prior to starting study drug. 4. Evidence of an active systemic bacterial, fungal, or viral infection requiring treatment. 5. Grade ≥ 2 peripheral neuropathy. 6. Major surgery within 4 weeks prior to starting study drug. 7. Prior solid organ or bone marrow progenitor cell transplantation. 8. Prior high-dose chemotherapy requiring stem cell rescue. 9. Anticancer therapy within 28 days or within 5 half-lives (whichever is shorter) prior to starting study drug. 10. Palliative radiation therapy within 14 days prior to starting study drug. 11. Live vaccine within 28 days prior to starting study drug. 12. Pregnant or a breastfeeding postpartum female.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of Participants Experiencing Adverse Events (AEs) | Up to approximately 10 months |
| Number of Participants Experiencing Dose-limiting Toxicities (DLTs) | Up to Day 21 |
| Number of Participants Experiencing Cycle Delay | Up to approximately 10 months |
| Number of Participants Experiencing Dose Reduction | Up to approximately 10 months |
| RDE of TGW101 | Up to approximately 10 months |
Secondary
| Measure | Time frame |
|---|---|
| Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) of TGW101-ADC and TRG001 | Up to approximately 10 months |
| Area Under the Concentration-time Curve From Time Zero to the end of the Dosing Interval (AUCtau) of TGW101-ADC and TRG001 | Up to approximately 10 months |
| Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) of TGW101-ADC and TRG001 | Up to approximately 10 months |
| Maximum Concentration (Cmax) of TGW101-ADC and TRG001 | Up to approximately 10 months |
| Trough Concentration (Ctrough) of TGW101-ADC and TRG001 | Up to approximately 10 months |
| Time to Maximum Concentration (Tmax) of TGW101-ADC and TRG001 | Up to approximately 10 months |
| Apparent Terminal Elimination Half-life (t1/2) of TGW101-ADC and TRG001 | Up to approximately 10 months |
| Steady-state Volume of Distribution (Vss) of TGW101-ADC and TRG001 | Up to approximately 10 months |
| Clearance (CL) of TGW101-ADC and TRG001 | Up to approximately 10 months |
| Accumulation Index of TGW101-ADC and TRG001 | Up to approximately 10 months |
| Overall Response Rate (ORR) | Up to approximately 10 months |
| Duration of Response (DOR) | Up to approximately 10 months |
| Progression-free Survival (PFS) | Up to approximately 10 months |
| Overall Survival (OS) | Up to approximately 10 months |
| Number of Participants Experiencing Antidrug Antibodies (ADAs) Against TGW101-ADC | Up to approximately 10 months |
Countries
United States
Contacts
CONTACTTagworks Pharmaceuticals
Outcome results
None listed